期刊文献+

缬沙坦治疗老年高血压伴有胰岛素抵抗的临床研究 被引量:1

下载PDF
导出
摘要 目的观察缬沙坦对老年高血压伴胰岛素抵抗(IR)患者的治疗作用及机制。方法将80例老年高血压伴IR的患者随机分为对照组及缬沙坦组,前者给予氨氯地平片,后者给予缬沙坦胶囊。观察两组的临床疗效,治疗前、后进行口服葡萄糖耐量试验(OGTT)、胰岛素释放试验(IRT)及空腹血糖(FBG)空腹胰岛素(FINS)胰岛素敏感指数(ISI)检测和动态血压监测,并进行统计学分析。结果①两组空腹血糖(FBG)均有下降趋势,但用药前后对比差异无显著意义(P>0·05)。②用药后缬沙坦组ISI有显著升高,与对照组相比差异有显著性(P<0·05)而对照组升高不显著(P>0·05)。③用药后缬沙坦组空腹胰岛素(FINS)显著降低(P<0·01)。④用药后缬沙坦组2小时血糖及2小时胰岛素均显著下降,与对照组相比有显著差异(P<0·05)。结论在高血压伴IR的患者中应用缬沙坦可以明显改善IR,可提高降压药物的治疗效果。
出处 《中国老年保健医学》 2011年第4期41-42,共2页 Chinese Journal of Geriatric Care
  • 相关文献

参考文献9

  • 1Reilly MP, Wolfe ML, Rhodes T et al. Measures of Insulin Resistance Add Incremental Value to the Clinical Diagnosis of Metabolic Syndrome in Association With Coronary At heroselemsis [ J ]. Circulation, 2004, 110(7) :803 -809.
  • 2Fujii N, Tsuchihashi K, Sasao H, et al. Insulin resistance functionally limit S endot helium dependent coronary vasod ilatinn in nondiabetic patient S[J]. Heart Vessels,2008,23( 1 ) :9 -15.
  • 3Sarzani R,Salvi F, Desst Fulgheri P,et al. Renin--angiotensin systen, natriuretie peptides, obesity, metabolic syndrome, and hyperension : an integrated view in humans[ J]. J Hypertens,2008,26 (5) : 831 - 843.
  • 4李光伟.2型糖尿病系列讲座 第三讲:胰岛素敏感性评估及其在临床研究中的应用[J].中华内分泌代谢杂志,2000,16(3):198-200. 被引量:195
  • 5刘晓民.胰岛素抵抗——一个重要的超学科问题[J].黑龙江医学,2004,28(6):401-402. 被引量:12
  • 6Definnzo RA. Fot)in JO. Andres R. Glucoseclamp lechnique :A method for quantifying insulin secretion and resisdlance [ J ]. Am J Phsial, 1979,237 (3) : E214 - E223.
  • 7Henriksen F~, Jacob S, Kinnick TR, et al. ACE inhibit ion and glu- cose transport in insulin resistant muscle: Roles of bradykinin and ni- tric oxide [J]. Am J Physiol, 1999, 277( 1 Pt 2) :11332.
  • 8Higashiura K, U ra N, M iyazaki Y, et al. Effect of an angiotensin Ⅱ receptor antagonist, candesartan, on insulin resistance and pressor- mechanises in essential hypertension [J]. J Hum Hypertens, 1999, 13 ( suppl 1) : S71.
  • 9Shiuehi T, Iwai M, Li HS, et al. Angiotensin Ⅱ type-Ⅰ receptor blocker valsart an enhances insulin sensit ivit y in skeletal muscles of diabetic mice[ J]. Hypertension, 2004, 43 : 1003 - 1010.

二级参考文献1

  • 1D. R. Matthews,J. P. Hosker,A. S. Rudenski,B. A. Naylor,D. F. Treacher,R. C. Turner. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man[J] 1985,Diabetologia(7):412~419

共引文献205

同被引文献22

  • 1罗子幸,陈伟强,郎江明,黄洁玲,赵华云.氯沙坦联用葛根素对原发性高血压左心室肥厚的逆转及胰岛素抵抗的影响[J].中西医结合心脑血管病杂志,2005,3(9):774-775. 被引量:3
  • 2华毅.二甲双胍、辛伐他汀对高血压伴胰岛素抵抗干预治疗对比[J].海南医学,2006,17(8):51-51. 被引量:4
  • 3王志国,杨晔.胰岛素抵抗与高血压研究进展[J].中华老年心脑血管病杂志,2006,8(7):495-496. 被引量:15
  • 4Cantor E J, Mancini EV, Seth R, et al. Oxidative stress and heart disease :cardiac dystunctinn,nutrition, and gene therapy. Curt Hy- pertens Rep,2003,5(2) :215-220.
  • 5Han KH, Hong KH, Park JH, et al. C-reactive protein promotes monocyte chemoattractant protein-l-mediated chemotaxis through upregulating CC chemokine receptor 2 expression in human mono- cytes. Circulation,2004,109(21 ) :2566-2571.
  • 6Diaz J J, Arguelles J, Malaga I, et al. C-reactive protein is elevated in the offspring of parents with essential hypertension. Arch Dis child,2007,92 (4) :304-308.
  • 7Xu T, Ju Z,Tong W,et al. Relationship of C-reactive protein with hypertension and interactions between increased C-reactive pro- tein and other risk factors on hypertension in Mongolian people, China. Cire J,2008,72 ( 8 ) : 1324-1328.
  • 8Kim JS, Kang TS, Kim JB, et al. Significant association of C-reac- tive protein with arterial stiffness in treated nondiabetic hyperten- sive patients. Atherosclerosis, 2007,192 ( 2 ) :401-406.
  • 9Savage DB,Tan GD,Acerini CL,et al. Human nmtabolic syndrome resulting from domlnant-negatlve mutations in the nuclear receptor peroxisome prolife rator-actived receprgamma. Diabetes, 2003,52 (4) :910-917.
  • 10朱全华.缬沙坦对高血压患者胰岛素抵抗的临床观察.中外健康文摘,2012,9(28):243-244.

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部